Technical Analysis for BOLD - Audentes Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 36.9 -6.68% -2.64
BOLD closed down 6.68 percent on Friday, March 22, 2019, on 1.37 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical BOLD trend table...

Date Alert Name Type % Chg
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Wide Bands Range Expansion -6.68%
Mar 21 Overbought Stochastic Strength -6.68%
Mar 20 Outside Day Range Expansion -4.16%
Mar 20 Wide Bands Range Expansion -4.16%
Mar 20 Overbought Stochastic Strength -4.16%
Mar 19 Wide Bands Range Expansion -4.16%
Mar 19 Overbought Stochastic Strength -4.16%

Older signals for BOLD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California.
Biotechnology Medical Specialties Organ Systems Rare Diseases Gene Therapy Hepatology Cardiac Arrhythmia Gene Therapy Products Pompe Disease Channelopathies Myopathy Treatment Of Pompe Disease
Is BOLD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 46.18
52 Week Low 17.95
Average Volume 513,427
200-Day Moving Average 31.2371
50-Day Moving Average 28.4882
20-Day Moving Average 34.637
10-Day Moving Average 37.272
Average True Range 1.82
ADX 44.27
+DI 34.1148
-DI 14.9303
Chandelier Exit (Long, 3 ATRs ) 34.49
Chandelier Exit (Short, 3 ATRs ) 30.5
Upper Bollinger Band 41.2848
Lower Bollinger Band 27.9892
Percent B (%b) 0.67
BandWidth 38.385541
MACD Line 3.0973
MACD Signal Line 3.0119
MACD Histogram 0.0854
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 27.8 Million
EPS -3.52
Price-to-Earnings (P/E) Ratio -10.48
Price-to-Sales 0.00
Price-to-Book 4.35
PEG Ratio -1.48
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.34
Resistance 3 (R3) 40.62 39.76 39.76
Resistance 2 (R2) 39.76 38.89 39.62 39.57
Resistance 1 (R1) 38.33 38.34 37.90 38.05 39.38
Pivot Point 37.47 37.47 37.26 37.33 37.47
Support 1 (S1) 36.04 36.60 35.61 35.76 34.42
Support 2 (S2) 35.18 36.05 35.04 34.23
Support 3 (S3) 33.75 35.18 34.04
Support 4 (S4) 33.47